Business
Processa Buys Vidya Therapeutics to Land VT-7208, an Oral BTK Inhibitor Aimed at Novartis
The all-stock deal, paired with a $200 million raise, hands Processa a once-daily, brain-penetrating BTK inhibitor targeting food allergy, chronic urticaria and multiple sclerosis.